PT -期刊文章盟特里Heiman-Patterson AU -绩效Cudkowicz盟Mamede De卡瓦略盟安琪拉其全称AU -欧尔Hardiman盟Carlayne杰克逊AU -诺亚Lechtzin盟Hiroshi Mitsumoto AU - Vincenzo Silani盟史黛西Rudnicki AU -莎拉Kulke盟Jinsy安德鲁斯AU -伦纳德Van den Berg TI -理解使用无创通气治疗肌萎缩性脊髓侧索硬化症在美国和欧洲:国际医生的调查结果(P5.071) DP - 2017年4月18日TA -神经病学PG - P5.071 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/P5.071.short 4100 - //www.ez-admanager.com/content/88/16_Supplement/P5.071.full所以Neurology2017 4月18日;首页88 AB -目的:理解首选的临床实践和识别障碍关于启动/使用无创通气(NIV)在肌萎缩性脊髓侧索硬化症(ALS)。背景:症状进展ALS患者需要呼吸支持,和合改善生活质量和延长生存。然而,和合起始时间和临床参数的差异和保险规定时可能会影响需求。设计/方法:25-item问卷调查是通过调查猴子®ALS专家鉴定通过加入尼尔(美国)和ENCALS(欧盟)。描述性统计/对比美国/欧盟反应进行了综述。结果:74/119(62.2%)的受访者治疗≥76 ALS患者/年(我们:40/71 (56.3%);欧盟:34/48 [70.8%])。当考虑和合、美国和欧盟专家价值直立FVC最正直人不同关于MIP(我们:2;欧盟:5)和隔夜脉搏血氧仪(美国:6;欧盟:2)。 In patients without respiratory symptoms, most US specialists initiate NIV at FVC/SVC <50% predicted upright VC (US: 41/60 [68.3%]; EU: 10/39 [25.6%];p<.001); no single criterion was identified by most EU physicians. When recommending NIV, US specialists more often refer patients to home agencies and trials/instructions occur at home (US: 39/57 [68.4%]; EU: 5/39 [12.8%];p<.001); EU specialists more often admit patients to hospital (US: 0/57 [0%]; EU: 16/39 [41.0%];p<.001). US specialists prefer to use certain ventilators non-invasively (US: 25/57 [43.9%]; EU: 5/39 [12.8%];p=.002); most EU specialists allow pulmonologists to decide (US: 11/57 [19.3%]; EU: 25/39 [64.1%];p<.001). Without influences of insurance/financial constraints, a greater number of US than EU specialists (US: 44/57 [77.2%]; EU: 6/39 [15.4%];p<.001) would alter when they prescribe NIV.Conclusions: NIV prescribing differs between the US and EU and may be influenced by insurance/financial constraints. Considering optimal NIV use influences patient survival and that differences in initiation and use also exist across the US, these differences can confound results in ALS treatment studies. This information may inform research, guideline revisions, and clinical use of NIV in ALS.Disclosure: Dr. Heiman-Patterson has nothing to disclose. Dr. Cudkowicz has received personal compensation for activities with Cytokinetics, Lilly, Astra Zenica, Biohaven, Genentech. Jama Neurology. Dr. De Carvalho has nothing to disclose. Dr. Genge has received personal compensation for activities with Novartis as a consultant and employee. Dr. Hardiman has received royalty payments from the Royal College of Surgeons in Ireland. Dr. Jackson has nothing to disclose. Dr. Lechtzin has nothing to disclose. Dr. Mitsumoto has received personal compensation for activities with Cytokinetics, Shinogi Pharma, and Biogen. Dr. Silani has nothing to disclose. Dr. Rudnicki has nothing to disclose. Dr. Kulke has nothing to disclose. Dr. Andrews has received personal compensation for activities with Cytokinetics, Inc. as an employee. Dr. van den Berg has received personal compensation for activities with Baxter as a consultant, and from Biogen and Cytokinetics as an advisory board member.